MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326724 | Name: Velpatasvir
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes.

Chemical Structure

Velpatasvir
Velpatasvir
CAS#1377049-84-7

Theoretical Analysis

MedKoo Cat#: 326724

Name: Velpatasvir

CAS#: 1377049-84-7

Chemical Formula: C49H54N8O8

Exact Mass: 882.4065

Molecular Weight: 883.02

Elemental Analysis: C, 66.65; H, 6.16; N, 12.69; O, 14.49

Price and Availability

Size Price Availability Quantity
50mg USD 90.00 Ready to ship
100mg USD 150.00 Ready to ship
200mg USD 250.00 Ready to ship
1g USD 950.00 Ready to ship
5g USD 3,250.00 Ready to Ship
10g USD 5,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
GS5816; GS-5816; GS 5816; Velpatasvir
IUPAC/Chemical Name
methyl ((R)-2-((2S,4S)-2-(5-(2-((2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidin-2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate
InChi Key
FHCUMDQMBHQXKK-CDIODLITSA-N
InChi Code
InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
SMILES Code
O=C(OC)N[C@H](C1=CC=CC=C1)C(N2[C@H](C3=NC=C(C4=CC5=C(C6=CC7=CC=C8C(NC([C@H]9N(C([C@H](C(C)C)NC(OC)=O)=O)[C@@H](C)CC9)=N8)=C7C=C6OC5)C=C4)N3)C[C@H](COC)C2)=O
Appearance
White to light yellow solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Velpatasvir (VEL, GS-5816) is a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 88.9 100.66
DMF 30.0 33.97
Ethanol 65.0 73.61
Ethanol:PBS (pH 7.2) (1:2) 0.3 0.37
Water 50.5 57.19
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 883.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Wang J, Du L, Zhang D, Zhou C, Zeng Y, Liu M, Cheng X, Song X, Chen H, Han N, Chen E, Tang H. Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients. J Virus Erad. 2024 Dec 3;10(4):100571. doi: 10.1016/j.jve.2024.100571. PMID: 39735164; PMCID: PMC11681871. 2: Han WM, Solomon S, Smeaton L, Avihingsanon A, Wagner-Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D. Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial. Clin Infect Dis. 2024 Dec 20:ciae627. doi: 10.1093/cid/ciae627. Epub ahead of print. PMID: 39702964. 3: Berkan-Kawińska A, Piekarska A, Berak H, Mazur W, Garlicki A, Tudrujek-Zdunek M, Lorenc B, Dybowska D, Socha Ł, Parfieniuk-Kowerda A, Flisiak R. Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide. Clin Exp Hepatol. 2024 Sep;10(3):165-169. doi: 10.5114/ceh.2024.141752. Epub 2024 Jul 29. PMID: 39697370; PMCID: PMC11650809. 4: Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People with Hepatitis C Virus. Clin Infect Dis. 2024 Dec 17:ciae595. doi: 10.1093/cid/ciae595. Epub ahead of print. PMID: 39688397. 5: Al-Naamani KM, Omar H, Al Busafi SA, Al Shuaili HH, Al-Naamani Z, Al-Khabori M, Said EA, AlKalbani AH, Kamath BR, Emad B, Daar S, Alhajri L, AlKalbani A, AlFarsi Z, Alzuhaibi H. Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross- Sectional, Multicenter Study. J Clin Med. 2024 Dec 5;13(23):7411. doi: 10.3390/jcm13237411. PMID: 39685869; PMCID: PMC11642565. 6: Sachithanandham J, Leep-Lazar J, Quinn J, Bowden K, Balasubramaniam P, Ward K, Ribeiro RM, Sulkowski MS, Balagopal A. Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation. J Infect Dis. 2024 Dec 4:jiae598. doi: 10.1093/infdis/jiae598. Epub ahead of print. PMID: 39656808. 7: Ma Y, Wang J, Du L, Tang H. Association between the systemic immune- inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C. Front Med (Lausanne). 2024 Nov 26;11:1486503. doi: 10.3389/fmed.2024.1486503. PMID: 39659620; PMCID: PMC11628305. 8: Slim J, Bellafiore P, Tempalski B, Rosmarin-DeStefano C, Leyden K, Torres J, Duprey S, Levaggi E. A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey. Open Forum Infect Dis. 2024 Nov 27;11(12):ofae645. doi: 10.1093/ofid/ofae645. PMID: 39605977; PMCID: PMC11600950. 9: Nicolas C, Domas Q, Pol S, Bardou-Jacquet E, Loustaud-Ratti V, Métivier S, Asselah T, Thabut D, Bourlière M, Mathurin P, Foucher J, Larrey D, Varaut A, Alric L, Bailly F, Muti L, Buchard B, Abergel A. Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study. Liver Int. 2024 Nov 12. doi: 10.1111/liv.16158. Epub ahead of print. PMID: 39530494. 10: M P, S D, C B, J K R, C SZ. Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy. Infection. 2024 Nov 11. doi: 10.1007/s15010-024-02433-4. Epub ahead of print. PMID: 39527344. 11: Tsui JI, Ludwig-Barron NT, James JR, Heo M, Sivaraj LB, Arnsten J, Lum PJ, Taylor LE, Mehta SH, Falade-Nwulia O, Feinberg J, Kim AY, Norton B, Page K, Litwin AH. Current Self-reported Pain Before and After Cure of Hepatitis C Among Persons Who Actively Inject Drugs. J Addict Med. 2024 Oct 30. doi: 10.1097/ADM.0000000000001398. Epub ahead of print. PMID: 39475112. 12: Table 3: Some drug interactions with DAAs for HCV infection. Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175. doi: 10.58347/tml.2024.1714f. PMID: 39466311. 13: Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults. Med Lett Drugs Ther. 2024 Oct 28;66(1714):e174. doi: 10.58347/tml.2024.1714e. PMID: 39466310. 14: Drugs for hepatitis C virus infection. Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-174. doi: 10.58347/tml.2024.1714a. PMID: 39466306. 15: Rosato V, Nevola R, Dallio M, Di Micco P, Spinetti A, Zeneli L, Ciancio A, Milella M, Colombatto P, D'Adamo G, Rosselli Del Turco E, Gallo P, Falcomatà A, De Nicola S, Pugliese N, D'Ambrosio R, Soria A, Colella E, Federico A, Brunetto M, Vespasiani-Gentilucci U, Aghemo A, Lampertico P, Izzi A, Mastrocinque D, Claar E. Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration. J Clin Med. 2024 Sep 28;13(19):5807. doi: 10.3390/jcm13195807. PMID: 39407867; PMCID: PMC11476466. 16: Arif A, Qureshi H. Rescue therapy with Sofosbuvir /Velpatasvir/ Voxilaprevir in a patient infected with Hepatitis C virus multidrug resistant variant-a much needed option for DAA-treatment failures in Pakistan? A case-report. J Pak Med Assoc. 2024 Oct;74(10):1875-1877. doi: 10.47391/JPMA.11595. PMID: 39407386. 17: Asghari N, Saei AK, Cordani M, Nayeri Z, Moosavi MA. Drug repositioning identifies potential autophagy inhibitors for the LIR motif p62/SQSTM1 protein. Comput Biol Chem. 2024 Dec;113:108235. doi: 10.1016/j.compbiolchem.2024.108235. Epub 2024 Oct 3. PMID: 39369612. 18: Inzaule S, Easterbrook P, Latona A, Ford NP, Irving W, Matthews PC, Vitoria M, Duncombe C, Giron A, McCluskey S, Lesi O, Tchamgoue S, Halford R, Adda D, Thomson E, Dusheiko G, Jordan MR. Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis. Clin Infect Dis. 2024 Dec 17;79(6):1437-1446. doi: 10.1093/cid/ciae431. PMID: 39361017; PMCID: PMC11650865. 19: Lei PK, Liu Z, Ung COL, Hu H. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis. BMC Gastroenterol. 2024 Sep 30;24(1):331. doi: 10.1186/s12876-024-03414-5. PMID: 39350091; PMCID: PMC11440749. 20: Ramzy S, Alshehri S, Abduljabbar MH, Althobaiti YS, Alzhrani RM, Almalki AH. An environmentally sustainable synchronous spectrofluorimetric method coupled with second derivative signal processing for simultaneous determination of velpatasvir and simeprevir in pharmaceutical and plasma samples. Spectrochim Acta A Mol Biomol Spectrosc. 2025 Feb 5;326:125202. doi: 10.1016/j.saa.2024.125202. Epub 2024 Sep 23. PMID: 39332169.